Images List Premium Download Classic

Metabolic Syndrome

Metabolic Syndrome-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Peptides having reduced toxicity that stimulate cholesterol efflux
The Regents Of The University Of California
October 05, 2017 - N°20170283480

The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e. G., apo ai and apo e), and having high selectivity for abca1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also ...
Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
Shionogi & Co., Ltd.
September 28, 2017 - N°20170275378

Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
Antibodies that bind il-23
Eli Lilly And Company
September 28, 2017 - N°20170275356

The present invention provides an antibody that binds to the p19 subunit of human il-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host ...
Metabolic Syndrome Patent Pack
Download + patent application PDFs
Metabolic Syndrome Patent Applications
Download + Metabolic Syndrome-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Metabolic Syndrome-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
Shionogi & Co., Ltd.
September 14, 2017 - N°20170260290

Provided is a humanized monoclonal antibody or an antibody fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
Fgf-8 for use in treating diseases or disorders of energy homeostasis
Technische Universität München
September 14, 2017 - N°20170258874

The present invention relates to polypeptides for use in treating diseases or disorders of energy homeostasis such as obesity, dyslipidemia, diabetes, insulin resistance, hyperglycemia or the metabolic syndrome. The invention also relates to polynucleotides encoding said polypeptides for use in treating diseases or disorders of energy homeostasis. Also provided by the present invention are pharmaceutical compositions comprising said polypeptides and ...
2-alkyloxy benzene formyl arylamine compound and pharmaceutical use thereof
Fudan University
September 07, 2017 - N°20170253564

2-alkoxy benzene formyl arylamine compounds and their pharmaceutical salts are disclosed. The compounds can act as sphingomyelin synthase (sms) inhibitors to treat diseases caused by abnormal increasing of sphingomyelin (sm). The pharmaceutically acceptable salts and pharmaceutical compositions of the compounds are used as active ingredients in drugs which can prevent and cure diseases caused by sm level abnormal increase. These ...
Metabolic Syndrome Patent Pack
Download + patent application PDFs
Metabolic Syndrome Patent Applications
Download + Metabolic Syndrome-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Metabolic Syndrome-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
Boehringer Ingelheim Vetmedica Gmbh
August 24, 2017 - N°20170239281

The present invention relates to combination of one or more sglt2 inhibitors or pharmaceutically acceptable forms and/or salts thereof and one or more dopamine receptor agonists or pharmaceutically acceptable forms and/or salts thereof, preferably in the treatment and/or prevention of a metabolic disorder of an equine animal, wherein more preferably the metabolic disorder is one or more ...
Chemical compounds and use thereof for improving muscular quality
Universite Paris 6 Pierre Et Marie Curie
August 10, 2017 - N°20170226151

Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical ...
N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase
Universiteit Leiden
August 10, 2017 - N°20170226058

Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are n-alkylated d-galacto, d-gluco- or l-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (“x”) on the methyloxy-carbon. These compounds display an increased inhibitory potency towards gcs, and/or an increased inhibitory potency towards gba2, and/or a decreased inhibitory potency ...
Modulation of laminin alpha-4 in the prevention, treatment, and management of metabolic syndromes
Illinois Institute Of Technology
August 03, 2017 - N°20170216409

The disclosure provides methods of preventing or treating metabolic syndrome in a subject by administering an effective amount of an inhibitor of laminin α4 expression, laminin α4 activity, or both.
Functionalized exendin-4 derivatives
Sanofi
August 03, 2017 - N°20170216406

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
Roasted laurina coffee, method for its preparation, and use for preventing metabolic syndrome
Illycaffe' S.p.a.
August 03, 2017 - N°20170216387

A roasted coffee of coffea arabica var. Laurina a powder of which comprises from 5. 0 to 10. 0 mg per gram of powder (mg/g) trigonelline and from 3. 0 to 8. 0 mg/g mono-caffeoylquinic acids (3-caffeoylquinic acid, 4-caffeoylquinic acid and 5-caffeoylquinic acid), the invention also relating to a beverage prepared with such roasted coffee, a method for the preparation and a use of such roasted ...
Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
Illycaffe' S.p.a.
July 27, 2017 - N°20170209539

In another aspect, the present invention is directed to a method for treating a patient suffering from a metabolic disorder such as the metabolic syndrome, type 2 diabetes, obesity, or prediabetes, and the metabolic sequale of these diseases including cardiovascular, cerebrovascular, renal and hepatic diseases, comprising the step of: administering to a patient suffering from the metabolic syndrome, type 2 diabetes, obesity, ...
Metabolic Syndrome Patent Pack
Download + patent application PDFs
Metabolic Syndrome Patent Applications
Download + Metabolic Syndrome-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Metabolic Syndrome-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease
Thymon, Llc
July 06, 2017 - N°20170190768

An isolated or synthetic antibody or ligand is provided that specifically binds to an epitope of a dissociated monomer of human tnf. Such binding disrupts assembly of the monomer into bioactive trimeric human stnf. A pharmaceutical composition contains one or more antibodies or ligands: (a) an antibody or ligand that specifically binds the tnf monomer-specific epitope having the sequence psdkpvah ...
Bacteroides cect 7771 and the use thereof in the prevention and treatment of excess weight, obesity ...
Consejo Superior De Investigaciones Cientificas
July 06, 2017 - N°20170189456

The invention relates to a strain of bacteroides uniformes with registration number cect 7771, and to the cellular constituents, metabolites and/or secreted molecules thereof. The invention also relates to a composition (nutritional or pharmaceutical) comprising at least one of the previous products. The invention further relates to the use of a strain of bacteroides uniforms, preferably cect 7771, or of the ...
Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
Boehringer Ingelheim International Gmbh
July 06, 2017 - N°20170189437

The present invention is directed to a pharmaceutical composition comprised of one or more sglt-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class i obesity, class ii obesity, class iii obesity, ...
Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and beta-cell dysfunction
Merck Patent Gmbh
July 06, 2017 - N°20170189354

The invention relates to a pharmaceutical composition comprising as active ingredient an effective amount of 2-methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the prophylaxis and therapy of type ii diabetes mellitus, the metabolic syndrome, diabetic nephropathy and/or neuropathy. Another object of the invention concerns the use of 2-methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the enhancement of ...
Human antigen binding proteins that bind to a complex comprising beta-klotho and an fgf receptor
Amgen Inc.
June 29, 2017 - N°20170183412

The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing b-klotho, and or fgf21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-klotho and at least one of (i) fgfr1c, (ii) fgfr2c and (iii) fgfr3c. In some embodiments the antigen ...
N-hydroxy bicyclic hydantoin carbamates as tools for indetification of serine hydrolase targets
The Scripps Research Institute
June 29, 2017 - N°20170183353

Provided herein are n-hydroxy bicyclic hydantoin carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of serine hydrolases. Furthermore, the subject compounds and compositions are useful for the treatment of one or more of cancer, pain, diabetes, obesity/metabolic syndrome, epilepsy, traumatic brain injury, and inflammation.
Agent for preventing or ameliorating diabetes
Kyushu University National University Corporation
June 29, 2017 - N°20170182110

An object of the present invention is to find a component that is safe and is capable of effectively exerting various effects such as prevention or amelioration of diabetes, prevention or amelioration of metabolic syndrome, amelioration of insulin resistance, inhibition of an increase in a postprandial blood sugar level, and inhibition of α-glucosidase activity. The present invention provides ...
Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods ...
Volant Holdings Gmbh
June 22, 2017 - N°20170173060

In one embodiment, the invention provides a method of regenerating organs and tissues in a subject suffering from one or more organ or tissue manifestations of glucose supply side associated metabolic syndrome, the method comprising: (a) confirming that the subject suffers from or is at risk for suffering from organ and/or tissue damage associated with a glucose supply side ...
Loading